TriangleGC511B CAR-T Cell (NCT07249879)
GC511B CAR-T Cell trial for Relapsed/Refractory Small Cell Lung Cancer (NCT07249879). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Small cell lung cancer responds to chemotherapy, then almost always returns within months, and second-line options are weak.
The idea: a CAR T cell for a target that small cell lung cancer displays and normal adult tissue mostly hides.
That target is DLL3, a protein on the surface of most small cell lung cancers. At the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing, a patient's T cells are engineered with a receptor for DLL3 and returned in one infusion after conditioning chemotherapy. Doses rise cautiously, one patient at a time at first.
A first study in people, for relapsed or refractory disease whose tumor tests positive. Ning Li leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.